Most Clicked BIO SmartBrief Stories


1. Teva to acquire Allergan's generic business unit

BIO SmartBrief | Jul 27, 2015

Teva Pharmaceutical Industries will acquire Allergan's generic business unit for about $40.5 billion. The acquisition will strengthen Teva's presence in the generic-drugs market and help with cost reductions. Teva will drop its bid for Mylan, CEO Erez Vigodman said. The Wall Street Journal (tiered subscription model) (07/27)


2. Novartis transfers experimental drugs to British startup

BIO SmartBrief | Jul 30, 2015

Novartis spun off three experimental drugs to Mereo BioPharma Group, a London-based biotech firm with $119 million in venture-capital funding. In return, Novartis receives equity in Mereo. The drugs are being developed as treatments for brittle bone syndrome, chronic obstructive pulmonary disease and hypogonadotrophic hypogonadism. FierceBiotech (07/29)


3. Naurex to be purchased by Allergan

BIO SmartBrief | Jul 27, 2015

Naurex, including its two experimental antidepressants, rapastinel and NRX-1074, will be bought by Allergan in a deal worth $560 million. Under terms of the agreement, Naurex is also eligible for undisclosed potential milestone fees. The deal, which is expected to be completed within the year, would spin off Naurex's platform for the discovery of drugs that improve neural cell communication. The Wall Street Journal (tiered subscription model) (07/26) PharmaTimes (U.K.) (07/26)


4. Merck to acquire cCAM Biotherapeutics

BIO SmartBrief | Jul 29, 2015

Merck will purchase cCAM Biotherapeutics in a deal worth $605 million. The deal boosts Merck's immunotherapy pipeline, giving it access to cCAM's monoclonal antibody, CM-24, which is in an early-stage trial as a treatment for advanced or recurrent cancers. Under the terms of the agreement, Merck will purchase all outstanding cCAM stock in exchange for a $95 million upfront cash payment, and shareholders of cCAM will receive up to $510 million in potential milestone fees. Genetic Engineering & Biotechnology News (07/28)


5. Report predicts 2020 drug trends

BIO SmartBrief | Jul 29, 2015

A report from EvaluatePharma predicts that nine of the 10 best-selling drugs by revenue worldwide in 2020 will be specialty drugs. The report also projects that biosimilar penetration of the market will be limited and AbbVie's Humira will be the top seller. Drug Channels (07/28)


6. Sanofi unit to purchase AstraZeneca's thyroid cancer drug

BIO SmartBrief | Jul 28, 2015

Sanofi's Genzyme unit agreed to pay as much as $300 million to acquire AstraZeneca's medullary thyroid carcinoma drug Caprelsa, or vandetanib. Under the terms of the deal, AstraZeneca is entitled to receive an upfront payment of $165 million and up to $135 million in potential milestone payments. The acquisition, which will be completed later this year, will strengthen Genzyme's endocrinology portfolio. Genetic Engineering & Biotechnology News (07/27) Reuters (07/27)


7. Boehringer to sell generics business to Hikma Pharmaceuticals

BIO SmartBrief | Jul 29, 2015

Boehringer Ingelheim's specialty generic drugs business unit, Roxane Laboratories and Boehringer Ingelheim Roxane, will be purchased by Hikma Pharmaceuticals in a stock-and-cash deal valued at $2.65 billion. The acquisition will make Jordan-based Hikma the sixth-largest provider of generic drugs in the U.S., the company said. Reuters (07/28)


8. Cancer drugs from Bristol-Myers, Kyowa Hakko Kirin to be combined in trial

BIO SmartBrief | Jul 31, 2015

Bristol-Myers Squibb and Japanese firm Kyowa Hakko Kirin have agreed to collaborate in a Phase I/II trial evaluating the combination of Kyowa's Poteligeo, or mogamulizumab, and Bristol-Myers' Opdivo, or nivolumab, as a treatment for advanced or metastatic solid tumors. The companies did not disclose financial terms of the agreement. PharmaTimes (U.K.) (07/30)


9. Juno Therapeutics' application for leukemia drug approved by FDA

BIO SmartBrief | Jul 31, 2015

Juno Therapeutics' investigational new drug application for JCAR015, a CAR-T therapeutic developed as a treatment for relapsed or refractory acute lymphoblastic leukemia, has been approved by the FDA. A midstage trial is scheduled to begin soon. Seeking Alpha (free registration) (07/30)


10. BIO's Jim Greenwood: More funding is needed for BARDA pandemic flu program

BIO SmartBrief | Jul 30, 2015

The development of vaccines and other medical countermeasures for pandemic flu, including highly pathogenic avian influenza, relies on funding through the Biomedical Advanced Research and Development Authority's pandemic influenza program, but money allocated for the program has declined significantly in recent years, BIO President and CEO Jim Greenwood writes. To ensure the nation's preparedness against possible disease outbreaks, the government should increase funding for BARDA's pan flu program and boost the transparency of future budget allocations, he writes. The Hill (07/29)




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more